Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 18439695.
- Also identified by DOI 10.1016/j.radonc.2008.04.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.
Medical subject headings
- Adenocarcinoma
- Antineoplastic Combined Chemotherapy Protocols
- Oxonic Acid
- Radiation-Sensitizing Agents
- Rectal Neoplasms
- Tegafur